Speaker Profile
Ph.D., CEO, BioAge
Biography
Kristen Fortney is the co-founder and CEO of BioAge, a clinical-stage biotechnology company developing a pipeline of treatments to extend healthy lifespan by targeting the molecular causes of aging. The company uses its discovery platform, which combines quantitative analysis of proprietary longitudinal human samples with detailed health records tracking individuals over the lifespan, to map out the key molecular pathways that impact healthy human aging. By targeting these pathways with a large and mechanistically diverse portfolio of drugs, BioAge will unlock opportunities to treat or even prevent diseases of aging in entirely new ways. Kristen’s scientific background is in aging biology and bioinformatics. She received her PhD in Medical Biophysics from the University of Toronto, followed by postdoctoral training at Stanford University where she was a fellow of the Ellison Medical Foundation / American Federation for Aging Research.
Session Abstract – PMWC 2022 Silicon Valley
- Hope or Hype? The Role of ML in Drug Discovery and Development (PANEL)
Session Chair: Ansuman Satpathy, Stanford University
- Marcel Hop, Genentech
- Mark Jacobstein, Immunai
- Stacie Calad-Thomson, BioSymetrics
- Andrea deSouza, Eli Lilly and Company - Advancing Research and Drug Discovery with UK Biobank
Session Chair: Asha Collins, DNAnexus
- Lucy Burkitt-Gray, UK Biobank
- Lisa McFerrin, AWS - Machine Learning for Novel Target Discovery: Unique Techniques Meet Unique Data
Session Chair: Alex Morgan, Khosla Ventures
- Lindsay Edwards, Relation Therapeutics
- Kristen Fortney, BioAge
- Quin Wills, Ochre Bio
- Joseph Rodgers, Fountain Therapeutics
- Calum MacRae, Atman Health - AI/ML in Clinical Trial Design, Patient Selection and Prediction of Outcomes (PANEL)
Session Chair: Peter Lipsky, Ampel Bio
- Nasim Eftekhari, City of Hope
- Mika Newton, xCures, Inc.
- William Oh, Sema4
- Treating Genetics as Data: Computable, Structured Results for Precision Medicine
- Peter DeVault, Epic - DeepConsensus: Sequence Transformers for Sequence Correction
- Andrew Carroll, Google - AI in Small Molecule Design and Screening (PANEL)
Session Chair: Petrina Kamya, Insilico Medicine
- Jim Edwards, Janssen
- Tommaso Mansi, Johnson & Johnson
- Martin Emanuel Bittner, Arctoris - PMWC 2022 Showcase
- Kevin Cho, Envisagenics, Inc.
- Poojitha Ojamies, Novartis
- Steve Harrison, Engine Biosciences
